← Back to guidelines
Cardiology26 papers

Post infarct angina

Last edited: 4/22/2026

Overview

Post-infarct angina occurs after a myocardial infarction, characterized by recurrent chest pain due to myocardial ischemia, often complicating recovery and contributing to adverse remodeling of the heart. 1

Diagnosis

  • Clinical Presentation: Recurrent chest pain post-MI, often triggered by exertion.
  • Electrocardiogram (ECG): May show ischemic changes but often nonspecific.
  • Echocardiography: Useful for assessing left ventricular function and wall motion abnormalities.
  • Nuclear Imaging: Stress perfusion imaging can identify areas of ischemia.
  • Coronary Angiography: Definitive for assessing coronary artery patency and identifying residual stenosis. 2
  • Management

  • Anti-ischemic Therapy: Beta-blockers (e.g., metoprolol 25-100 mg/day), ACE inhibitors (e.g., lisinopril 5-20 mg/day), and calcium channel blockers (e.g., amlodipine 5-10 mg/day) to reduce myocardial oxygen demand and improve symptoms. 1
  • Antiplatelet Agents: Aspirin and P2Y12 inhibitors (e.g., clopidogrel 75 mg/day or ticagrelor 90 mg bid) to prevent thrombosis.
  • Statins: To reduce cholesterol and inhibit atherosclerosis progression (e.g., atorvastatin 20-80 mg/day).
  • Revascularization: Consider PCI or CABG if significant residual stenosis is identified.
  • Management of Remodeling: Targeting pathways like VEGF and RAGE signaling may offer future therapeutic avenues, though specific drugs are not yet established. 2
  • Special Populations

  • Elderly: Similar management principles apply, with careful titration of medications due to comorbidities and polypharmacy risks. 1
  • Comorbidities: Management should consider interactions with conditions like diabetes and hypertension, emphasizing tight glycemic and blood pressure control. 1
  • Key Recommendations

  • Initiate beta-blockers, ACE inhibitors, and statins to reduce myocardial remodeling and improve outcomes post-MI. (Evidence: Strong 1)
  • Use antiplatelet therapy including aspirin and a P2Y12 inhibitor to prevent recurrent ischemic events. (Evidence: Strong 1)
  • Consider revascularization procedures (PCI/CABG) for patients with significant residual coronary artery stenosis contributing to angina. (Evidence: Moderate 2)
  • References

    1 Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovascular research 2012. link 2 Tsoporis JN, Izhar S, Proteau G, Slaughter G, Parker TG. S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation. Journal of molecular and cellular cardiology 2012. link

    Original source

    1. [1]
    2. [2]
      S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation.Tsoporis JN, Izhar S, Proteau G, Slaughter G, Parker TG Journal of molecular and cellular cardiology (2012)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG